欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (10): 1429-1435.doi: 10.12092/j.issn.1009-2501.2025.10.015

• 综述与讲座 • 上一篇    下一篇

莱博雷生在失眠治疗中的研究进展

郭丽佳1,2,东子暄1,2,吴惠珍1,2   

  1. 1河北医科大学研究生学院,石家庄  050017,河北;2河北省人民医院药学部,河北省临床药学重点实验室,石家庄  050051,河北

  • 收稿日期:2024-10-21 修回日期:2024-12-22 出版日期:2025-10-26 发布日期:2025-10-15
  • 通讯作者: 吴惠珍,女,主任药师,硕士生导师,研究方向:临床药学。 E-mail: 13582005982@163.com
  • 作者简介:郭丽佳,女,硕士研究生,研究方向:临床药学。 E-mail: guolijia_2001@163.com
  • 基金资助:
    河北省医学适用技术跟踪项目(GZ2023035)

Research progress of lemborexant in the treatment of insomnia disorder

GUO Lijia1,2, DONG Zixuan1,2, WU Huizhen1,2   

  1. 1Graduate School of Hebei Medical University, Shijiazhuang 050017, Hebei, China; 2Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang 050051, Hebei, China
  • Received:2024-10-21 Revised:2024-12-22 Online:2025-10-26 Published:2025-10-15

摘要:

莱博雷生是用于治疗失眠的新药。它是一种双重食欲素受体拮抗剂,通过竞争性结合两种食欲素受体OX1R和OX2R,抑制食欲素神经传递,调节睡眠-觉醒节律。本文全面综述了莱博雷生的药物靶点发现、基本情况、临床研究、安全性评估及局限性分析,旨在为临床提供对该药物研究现状和成果的全面了解。

关键词: 莱博雷生, 失眠, 食欲素受体拮抗剂, 药代动力学, 临床研究

Abstract:

Lemborexant is a new drug for the treatment of insomnia. It is a dual orexin receptor antagonist that competitively binds to two orexin receptors, OX1R and OX2R, inhibits orexin neurotransmission, and regulates the sleep-wake rhythm. This article comprehensively reviews the discovery of the drug target, basic information, clinical studies, safety assessment, and limitation analysis of lemborexant, aiming to provide a comprehensive understanding of the current research status and achievements of this drug in clinical practice.

Key words: lemborexant, insomnia, orexin receptor antagonist, pharmacokinetics, clinical study

中图分类号: